Just in time for Easter, the market delivered two consecutive sessions of gains. All three of the major U.
Though Trevena Inc (NASDAQ:TRVN) released positive Phase III trial data read-outs yesterday, shares are dropping 8% today. From the viewpoint of Aegis analyst …
Trevena Inc (NASDAQ:TRVN) shares collapsed today, falling nearly 40%, after the pharmaceutical company reported that both Phase 3 oliceridine (Olinvo) trials in post-surgical pain met …
In a research report issued today, Cowen analyst Ritu Baral reiterated an Outperform rating on shares of Trevena Inc (NASDAQ:TRVN) and slightly raised the price …
Biotechnology company Trevena, Inc. (NASDAQ:TRVN) discovers and develops therapeutics to target G protein coupled receptors, or GPCRs.
Quick SPDR S&P 500 ETF Trust (NYSE ARCA:SPY) forecast update: Back on November 10th 2014 we predicted a spring 2015 high of 2181 …